Vasculitis & polymyalgia rheumatica
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial
Primary result · Remission (BVAS v3 of 0 and prednisone ≤7.5 mg/d)Result — go to the resultRR for remission 1.05 95% CI 0.78–1.42Authors' conclusion
Rituximab was not superior to a conventional remission induction strategy in EGPA.
Study context
- Population
- Patients with eosinophilic granulomatosis with polyangiitis (EGPA), newly diagnosed or relapsing, with active disease (Birmingham Vasculitis Activity Score (BVAS) ≥3), Francerandomly assigned
- Participants
- 105 patients
- Comparison
- GC plus RTX vs conventional strategy for remission induction
- Primary endpoint
- Remission: BVAS v3 of 0 and prednisone ≤7.5 mg/d
- Follow-up
- Day 180
Methodological detailsphase 3, multicentre, double-blind, superiority
- Phase 3
- Multicentre
- Double-blind
- Superiority
Primary result
As reported in the abstract
Remission (BVAS v3 of 0 and prednisone ≤7.5 mg/d)
RR for remission
1.05
95% CI 0.78–1.42
P = 0.75
Events by treatment group
Rituximabvs Conventional strategy
RR for remission 1.05 (95% CI 0.78–1.42); P = 0.75
Secondary outcomes
Duration of remission
P = 0.41
Remission · day 360
- Results were similar at day 360
All relapse and major relapse rates
- Similar between the 2 groups
Average daily GC dose
- No statistically significant difference
Safety
Adverse events
- No statistically significant differences in rates between treatment groups
Original publication
Rituximab Versus Conventional Therapy for Remission Induction in Eosinophilic Granulomatosis With Polyangiitis : A Randomized Controlled Trial. Ann Intern Med. Published 29 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →